Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots of eyes watching and loading as we speak,
this board should be very busy but its not.
i already flipped this once today waiting to get back in.
The dip, last call before rocket boosters all activate
Next leg up will be violent
Sound all alarms, Cancer Breakthrough
Shorts all going to hell where they belong
Your the dumping shortie loser, see you @5$
Once the $1,50 wall gets soaked up your all in trouble
Good riddance shortie, whales soaking up the float for the main event
So that tells me lots of bag holders who are not going to sell this is a momo play I’m never in stocks that long anyways
Hi sub, selling some this morning, learned not to be greedy long ago.
Great call on this one old buddy...been watching since $1.
$RNAZ perspective. We are only at .035 pre reverse split. Let that sink dude!!!
Diamond$ in the $ky $weet$$$
$hort $queeze $weet$$$ bid$ not getting filled$$$
FDA DECLARE THE HOLY GRAIL IN RNA CANCER RESEARCH FOR THE TERMINALLY ILL CANCER PATIENTS NEED TO SEE THE LIGHT OF HOPE
GOD BLESS RNAZ TTX-MC138 MADE IN THE USA
TTX-MC138 NEW HOPE FOR TERMINALLY ILL CANCER PATIENTS
RNAZ The Stars and Stripes", "Old Glory", Star-Spangled Banner". Breakthrough Declared
TransCode Therapeutics Inc Stock (RNAZ) Forecast
The TransCode Therapeutics Inc (RNAZ) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $25.73, representing a +1834.46% increase from the current price of $1.33. The highest analyst price target is $51.20, and the lowest is $0.2584.
https://stockscan.io/stocks/RNAZ/forecast
Looking all but up!
https://coincodex.com/stock/RNAZ/price-prediction/
This going back over $4 not sure when but it will. Hopefully to $100 lol
TransCode Therapeutics Inc (RNAZ) is an excellent investment, but the stock is overvalued/undervalued right now
Preston Campbell
May 7, 2024
Companies
While TransCode Therapeutics Inc has underperformed by -0.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNAZ fell by -99.67%, with highs and lows ranging from $309.60 to $0.42, whereas the simple moving average fell by -95.88% in the last 200 days.
Analysis of TransCode Therapeutics Inc (RNAZ)
TransCode Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -759.85% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.28, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and RNAZ is registering an average volume of 534.06K. On a monthly basis, the volatility of the stock is set at 13.88%, whereas on a weekly basis, it is put at 21.01%, with a gain of 38.79% over the past seven days. Furthermore, long-term investors anticipate a median target price of $3.00, showing growth from the present price of $0.81, which can serve as yet another indication of whether RNAZ is worth investing in or should be passed over.
How Do You Analyze TransCode Therapeutics Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.53%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 0.24% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RNAZ shares are owned by institutional investors to the tune of 0.24% at
RNAZ BULLS GOING TO WAR AGAINST CANCER
They are all in hell where they belong forever, May they all rot in vomit
There are no shorts in RNAZ, this is going up after a 99% drop over the past few months:
Shares Short (4/15/2024) 4 18.55k
Short Ratio (4/15/2024) 4 0.06
Short % of Float (4/15/2024) 4 0.32%
Short % of Shares Outstanding (4/15/2024) 4 0.32%
Shares Short (prior month 3/15/2024) 4 174.75k
Unleash hell News, and burn the short vomits to hell where they belong forever,
HELL IS WHERE THE SHORTS BELONG, ROT IN HELL
1.29 X 1.30
Hell is where the shorts belong for suppressing the cure to cancer
Yo G"s MOASS unleash hell on all shorts
Once that $1.04 wall gets busted down watch out!!! Breakout is imminent
Shorties out of ammo, Hell is where they all belong
Flippers are out of business, ready for next leg up 2$
Chomp chomp chomp away!!! News is coming baby!!!
WOOOOW ANOTHER 71000 SHARE BUY @1.05 $$$$$$$$$$$$$$$3
It's a miracle drug that deserves lots of attention from the scientific community, Congrats to all management and research for all their hard work and dedication to make this miracle happen
New hope for terminally ill cancer patients
We know of no other RNA companies currently in clinical development that have an exclusive focus on cancer and whose pipelines are not limited to a single RNA technology such as siRNA or mRNA vaccines. By contrast, TransCode’s pipeline spans a spectrum of RNA technologies and includes ncRNAs, RNA vaccines, CRISPR technology, and immunostimulatory RNAs solely for oncology
It will turn nuclear with news, Go RNAZ
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3011
|
Created
|
04/27/21
|
Type
|
Free
|
Moderators MetaMonster |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |